Sarepta Therapeutics(SRPT)

• Portfolio of three FDA-approved DMD therapies (EXONDYS 51, VYONDYS 53, AMONDYS 45) with peak revenue potential and extended patent protection through 2028-2034, providing revenue stability
• Strong R&D engine with 71% R&D intensity and active pipeline spanning exon-skipping, gene therapy, and adjacent modalities (infectious disease, cardiovascular)
• Public company status with $1.2B FY2025 revenue (+29% YoY) and $428M cash position enables resource allocation and career progression visibility

Generated by Claude from Sarepta Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.